热门资讯> 正文

BeOne Pharmaceuticals因肝癌资产获得孤儿药地位

2026-03-24 00:30

The US FDA has granted orphan drug status to BeOne Medicine's (ONC) BGB-B2033 for hepatocellular carcinoma, the most common type of liver cancer.
BGB-B2033 is an IgG-based bispecific antibody targeting GPC3 and 4-1BB in phase 1.
BeOne says that BGB-B2033's anti-tumor activity can potentially be enhanced with the company's Tevimbra (tislelizumab), an IgG4 anti-PD-1 monoclonal antibody.

More on BeOne Medicines

Tracking Baker Brothers Portfolio - Q4 2025 Update
BeOne Medicines: Guidance Weighs But Multiple Catalysts In 2026
BeOne Medicines AG (ONC) Q4 2025 Earnings Call Transcript
Most oversold healthcare stocks above $10B on Wall Street amid Middle East disruptions
BeiGene Q4 2025 Earnings Preview

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。